Navigation Links
ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Date:8/30/2007

FREMONT, Calif., Aug. 30 /PRNewswire/ -- ARYx Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering will be sold by ARYx Therapeutics.

The underwriters of the offering will be Morgan Stanley & Co. Incorporated acting as sole book runner and lead manager and CIBC World Markets Corp., Jefferies & Company, Inc. and Leerink Swann & Co., Inc. acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com or by contacting the prospectus department at 180 Varick Street, New York, NY 10014 Attn: Prospectus Department.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the effic
'/>"/>

SOURCE ARYx Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. PCR Polymerases Application Profiles
3. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
4. Obtaining a contour map from multifiles or 3D data in DataMax
5. Successful stabilization of gene expression profiles
6. Madison biotech NimbleGen files for IPO; one of states best-funded firms
7. Third Wave files countersuit vs. Digene in patent case
8. TomoTherapy files registration statement for IPO
9. Merge files financial reports by market opening
10. The Why Files celebrates decade of science exploration
11. Third Wave files patent suits against Digene, Chiron and Bayer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015 Specialty Pharmacy ... and been admitted to BPA Worldwide as a ... will track audience data for Specialty Pharmacy Times ... , “By becoming a member of BPA Worldwide, ... providing our clients with the most reliable, unequaled ...
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... 21, 2015 W. R. Grace ... facility in Worms, Germany has received good manufacturing ... of the International Pharmaceutical Excipient Council (IPEC) Foundation. ... produce its SYLOID® FP brand of pharmaceutical grade ... following the Curtis Bay, Maryland (USA) and Sorocaba, ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2
... Sciences Holdings, Inc. (OTC Bulletin Board: ... development and commercialization of novel drugs in the therapeutic ... that it has submitted a full proposal to the ... BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense .  It ...
... imaging system, scientists have tracked a group of near-infrared ... the body and out again, providing a description of ... could be used in developing therapeutic agents to treat ... of the health effects of air pollution. ...
... 2010 Financial Results ... ... --> ... // Results are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
Cached Biology Technology:Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3Oncothyreon Reports Third Quarter 2010 Financial Results 4Oncothyreon Reports Third Quarter 2010 Financial Results 5Oncothyreon Reports Third Quarter 2010 Financial Results 6Oncothyreon Reports Third Quarter 2010 Financial Results 7Oncothyreon Reports Third Quarter 2010 Financial Results 8Oncothyreon Reports Third Quarter 2010 Financial Results 9Oncothyreon Reports Third Quarter 2010 Financial Results 10Oncothyreon Reports Third Quarter 2010 Financial Results 11
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
Breaking Biology News(10 mins):FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
... with injury better than others. A flesh wound or muscle ... will heal. The prognosis for a heart attack, on the ... been thought that cardiac cells (cardiomyocytes) lack the capacity for ... from a heart attack. However, recent evidence suggests that the ...
... Therapeutics, today announced the grant of a major patent, ... Trademark Office on microarray products allowing the specific detection ... for the discovery of alternative RNA splicing events. The ... of five oligonucleotides for the detection of each splice ...
... results in irreversible damage to the heart that ... results from the limited ability of the myocardium ... from Tufts University now document the existence of ... stem cells with therapeutic potency for myocardial tissue ...
Cached Biology News:Heart repair gets new muscle 2Products containing specific probes for detecting alternative splice forms protected 2
... with an Affinity Chitin-binding Tag) utilizes the ... elements (termed inteins) to purify recombinant proteins ... 1 and 2). This system distinguishes itself ... ability to separate a recombinant protein from ...
... Skeletal Myogenesis Kit provides the reagents ... into mature skeletal myotubes. By efficiently ... a valuable tool in studies examining ... developing strategies for muscle cell replacement ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
... of E-PAGE Gels easier and more efficient ... and several types of pre-cut pre-assembled membrane/filter ... x 13.5 cm E-PAGE Gels*. The available ... for western transfer of proteins (Figure 1 ...
Biology Products: